It took 12 months for Teva to gain FTC approval to buy Allergan's U.S. generics business. Future mergers could face the same long scrutiny.
The pharmaceutical company announced that it will increase its patient assistance program in hopes of quelling a growing backlash over its drug pricing.
Despite Teva Pharmaceuticals (TEVA) losing two patents for its Copaxone drug, Leerink said generics won't challenge the company until 2018.
The pharma company has been increasing the price of the epinephrine injector since 2007, so why are people finally taking notice?